News archive for Neuro-SysMed
Did you know that UiB coordinates a European initiative to target the cause of MS?
Honorary Doctor Alberto Ascherio led the research that demonstrated a connection between the Epstein-Barr virus and Multiple Sclerosis (MS). Here he answers five key questions about this topic.
During 2017-2019, systematic differences in high efficacy MS-treatment strategies were preferred in Oslo (cladribine) and Bergen (rituximab). Comparisons of long-term (median 4.5 years) effects from these different treatments showed a 2.7 higher risk for new MRI disease activity after four years in the cladribine group (n=132) compared to rituximab group (n=168).
- June 2024 (3)
- May 2024 (3)
- October 2023 (1)
- September 2023 (1)
- May 2023 (2)
- December 2022 (1)
- November 2022 (2)
- March 2022 (1)